Company News
-
Dec 29, 2023Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
-
Mar 29, 2023Clover Announces Corporate Updates and Full Year 2022 Financial Results
-
Feb 20, 2023Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
-
Feb 14, 2023Clover Launches COVID-19 Booster Vaccine in the People's Republic of China
-
Jan 16, 2023Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-
Nov 30, 2022Clover's Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
-
Oct 9, 2022Clover Provides Update on 2022 Corporate Milestones
-
Sep 20, 2022Clover's COVID-19 Vaccine Candidate Receives European Union GMP Certificate
-
Sep 20, 2022Clover's Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
-
Sep 6, 2022Clover's COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
-
Aug 30, 2022Clover's COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
-
Aug 25, 2022Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
-
Jun 27, 2022Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster
-
Jun 13, 2022Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines
-
Jun 5, 2022Clover Provides Update on 2022 Corporate Milestones
-
May 31, 2022Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
-
May 5, 2022Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
-
Apr 27, 2022Clover Appoints LiongHo Chua as President of Greater China
-
Apr 20, 2022Clover’s Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease
-
Apr 19, 2022Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022
